General Information of Drug (ID: DMP6BSH)

Drug Name
Orotic acid Drug Info
Synonyms
65-86-1; 6-Carboxyuracil; Oropur; Orodin; Orotonin; Orotonsan; Oroturic; Orotyl; Whey factor; Vitamin B13; 2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid; Uracil-6-carboxylic acid; 6-Uracilcarboxylic acid; Animal galactose factor; Orotsaeure; Molkensaeure; Uracil-6-carbosaeure; 4-Pyrimidinecarboxylic acid, 1,2,3,6-tetrahydro-2,6-dioxo-; 2,6-Dihydroxypyrimidine-4-carboxylic acid; 2,6-Dihydroxy-4-pyrimidinecarboxylic acid; Orotsaeure [German]; Acidum oroticum; Acide orotique; Acido orotico; Acidum oroti
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
967
ChEBI ID
CHEMBL16742
CAS Number
CAS 65-86-1
TTD Drug ID
DMP6BSH

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Artemisinin DMOY7W3 Malaria 1F40-1F45 Approved [5]
Leflunomide DMR8ONJ Arthritis FA20 Approved [6]
Teriflunomide DMQ2FKJ Hyperlipidaemia 5C80 Approved [7]
Atovaquone DMY4UMW Fungal infection 1F29-1F2F Approved [8]
Avastin+/-Tarceva DMA86FL Non-small-cell lung cancer 2C25.Y Phase 3 [9]
Acetate Ion DMD08RH Discovery agent N.A. Investigative [10]
B-Octylglucoside DMMO75G Discovery agent N.A. Investigative [10]
Orotate DMMB29S Discovery agent N.A. Investigative [11]
Lauryl Dimethylamine-N-Oxide DM3W2OE Discovery agent N.A. Investigative [10]
1,4-Naphthoquinone DMTCMH7 Discovery agent N.A. Investigative [9]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [12]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [13]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [14]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [15]
Pioglitazone DMKJ485 Amyotrophic lateral sclerosis 8B60.0 Approved [16]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [17]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [18]
Menadione DMSJDTY Vitamin K deficiency 5B59 Approved [19]
Arsenic DMTL2Y1 N. A. N. A. Approved [20]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [21]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Aspirin DM672AH Acute coronary syndrome BA41 Approved [22]
Methotrexate DM2TEOL Anterior urethra cancer Approved [23]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [24]
Paclitaxel DMLB81S Breast carcinoma Approved [25]
Allopurinol DMLPAOB Gout FA25 Approved [25]
Bumetanide DMRV7H0 Congestive heart failure BD10 Approved [25]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [25]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [25]
Tetracycline DMZA017 Acne vulgaris ED80 Approved [25]
Ranitidine DM0GUSX Gastric ulcer DA60 Approved [26]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) TT3PQ2Y PYRD_PLAF7 Inhibitor [2]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Regulatory-associated protein of mTOR (RPTOR) OT4TQZ9F RPTOR_HUMAN Post-Translational Modifications [3]
Solute carrier family 22 member 7 (SLC22A7) OTKTNH1W S22A7_HUMAN Regulation of Drug Effects [4]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4690).
2 Structure-activity relationships of pyrimidines as dihydroorotate dehydrogenase inhibitors. Biochem Pharmacol. 1988 Oct 15;37(20):3807-16.
3 Proliferating effect of orotic acid through mTORC1 activation mediated by negative regulation of AMPK in SK-Hep1 hepatocellular carcinoma cells. J Toxicol Sci. 2012;37(4):813-21. doi: 10.2131/jts.37.813.
4 Benzoic acid and specific 2-oxo acids activate hepatic efflux of glutamate at OAT2. Biochim Biophys Acta. 2013 Feb;1828(2):491-8. doi: 10.1016/j.bbamem.2012.08.026. Epub 2012 Sep 7.
5 The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
6 Identification and characterization of potential new therapeutic targets in inflammatory and autoimmune diseases. Eur J Biochem. 1999 Dec;266(3):1184-91.
7 Expression and characterization of E. coli-produced soluble, functional human dihydroorotate dehydrogenase: a potential target for immunosuppression. J Mol Microbiol Biotechnol. 1999 Aug;1(1):183-8.
8 Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane-associated N-terminal domain. Protein Sci. 2004 Apr;13(4):1031-42.
9 Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem Biol Interact. 2000 Jan 3;124(1):61-76.
10 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
11 Antimalarial activity of orotate analogs that inhibit dihydroorotase and dihydroorotate dehydrogenase. Biochem Pharmacol. 1992 Mar 17;43(6):1295-301.
12 DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
13 Nuclear and Mitochondrial DNA Methylation Patterns Induced by Valproic Acid in Human Hepatocytes. Chem Res Toxicol. 2017 Oct 16;30(10):1847-1854. doi: 10.1021/acs.chemrestox.7b00171. Epub 2017 Sep 13.
14 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
15 The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
16 Pioglitazone, a PPAR agonist, attenuates PDGF-induced vascular smooth muscle cell proliferation through AMPK-dependent and AMPK-independent inhibition of mTOR/p70S6K and ERK signaling. Biochem Pharmacol. 2016 Feb 1;101:54-70. doi: 10.1016/j.bcp.2015.11.026. Epub 2015 Nov 28.
17 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
18 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
19 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
20 Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
21 The human myometrium differentially expresses mTOR signalling components before and during pregnancy: evidence for regulation by progesterone. J Steroid Biochem Mol Biol. 2014 Jan;139:166-72. doi: 10.1016/j.jsbmb.2013.02.017. Epub 2013 Mar 26.
22 Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 2002 Nov;303(2):534-9.
23 Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
24 Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
25 Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8.
26 A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.